請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52936
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 賴裕和 | |
dc.contributor.author | Chia-Yu Yen | en |
dc.contributor.author | 嚴家玉 | zh_TW |
dc.date.accessioned | 2021-06-15T16:34:53Z | - |
dc.date.available | 2018-09-25 | |
dc.date.copyright | 2015-09-25 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-08-12 | |
dc.identifier.citation | 中文部分
台灣癌症登記中心(2012)•96-100癌症五年相對存活率•取自http:// tcr.cph.ntu. edu.tw/uploadimages/Survival_96_100.pdf 王映之(2010)•末期癌症病人靈性安適感與症狀的相關性•未發表的碩士論文•臺北:臺北醫學大學護理學研究所。 王淑怡(2008)•非小型細胞肺癌之症狀群集之探討•未發表的博士論文•臺北:臺北醫學大學醫學科學研究所。 李芸湘(2013)•晚期肺癌病人之主要照顧者的照顧負荷、負荷型態及其相關因素之探討-縱貫式研究•未發表的博士論文•臺北:臺灣大學醫學院護理學研究所。 李政洋、陳虹汶、李玉嬋、唐婉如、方俊凱(2011)•癌症照顧的自殺防治•內科學誌,22,335−343 吳淑芬、林佑樺、李來涼、簡婉儀(2014)•婦科癌症患者的疾病不確定感與憂鬱之相關性探討•護理暨健康照護研究,10(2),83−93,doi:10.6225/JNHR. 10.2.83。 武芮竹(2011)•肝癌病患人格特質與疾病不確定感之探討•未發表的碩士論文•臺北:臺灣大學醫學院護理學研究所。 周繡玲、姚鍾太、楊立華、朱基銘、趙婉青(2010)•肺癌病人化療期間疲憊、睡眠障礙及情緒困擾之探討•腫瘤護理雜誌,10(2),23-38。 邱萱辰(2009)•肺癌主要照顧者照護需求及其相關因素探討•未發表的碩士論文•臺北:臺灣大學醫學院護理學研究所。 施穎銘、陳育民(2008)•非小細胞肺癌的標靶治療•內科學誌,19(1),8-13。 胡懷文、陳美伶、廖玟君(2008)•大腸直腸癌病患口服化學治療服藥遵從性之 初探性研究•中山醫學雜誌,19,159-173。 高淑雰、宋易珍、黃于芳、張芳瑜、張月娟(2013)•肺癌病人照護需求及其相關因素之探討•榮總護理,30(4),329-339,doi: 10.6142/VGHN.30.4.329。 許淑蓮、黃秀梨(1996)•Mishel疾病不確定感量表之中文版測試•護理研究,4(1),59-68。 陳伊倩、簡姿娟、洪秀吉(2012)•癌症病患不確定感之照護策略•秀傳醫學雜誌,11(3&4),137-143。 陳金鈴(2015)•癌症病患化學治療期間身心困擾相關因素探討•未發表的碩士論文•高雄:義守大學管理學院研究所。 陳佩英、史麗珠、王正旭、賴裕和、張獻崑、陳美伶(1999)•疼痛對癌症病患焦慮與憂鬱之影響•臺灣醫學,3(4),373-382。 陳淙祺(2014)•在台灣因表皮生長因子酪氨酸激酶抑制劑上市對非小細胞肺癌病人延長存活期之臨床表徵評估•未發表的碩士論文•臺中:中山醫學大學醫學院醫學研究所。 陳偉武、洪敏瑛、陳幼貴(2010)•肺癌治療回顧及發展•腫瘤護理雜誌,10(2), 39-54。 黃怡靜(2011)•早期肺癌術後患者的症狀嚴重度、心理困擾與照護需求之探討• 未發表的碩士論文•臺北:臺灣大學醫學院護理學研究所。 楊文琪(1996)•接受化學治療之血液腫瘤病患其身心社會困擾與自我照顧、社會支持的相關性探討•未發表的碩士論文•臺北:陽明大學護理學研究所。 楊志新(2008)•晚期非小細胞肺癌的標靶治療•臺灣醫學,12(1),22-26。 楊蓓菁、邱碧如、石富元(2008)•口腔癌術後病患出院前對其疾病不確定感之探討•輔仁醫學期刊,6(2),53−68。 詹瑞君、廖幼婕、李芸湘、賴裕和(2014)•接受標靶治療的肺癌病患身體心像改變之臨床照護•護理雜誌,61(4),90-96,doi: 10.6224/JN.61.4.90。 廖斌志、陳冠宇、林家齊、楊志新(2014)•表皮生長因子接受器酪胺酸酶抑制劑於晚期肺癌治療•臺灣醫學,18(6),654-660。 廖慧娟、楊喬茵、顧雅利、蕭雅莉、江明珠(2005)•肝癌病患不確定感之相關因素探討•長庚護理,16(3),252-263。 趙慧玲、黃惠如、謝碧晴、蘇慧芳(2013)•癌症病人情緒困擾及其相關因素探討•輔仁醫學期刊,11(3),205-214。 衛生福利部(2015,4月13日)•民國102年度死因統計年報.取自http: // www. mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=5150 衛生福利部國民健康署(2014,2月)•民國100年癌症登記年報.取自http:// www. hpa.gov.tw/BHPNet/Web/Stat/StatisticsShow.aspx?No=201404160001 衛生福利部國民健康署(2015,2月)•民國101年癌症登記年報.取自http:// www.hpa.gov.tw/BHPNet/Portal/File/StatisticsFile/201504290915220898/101%e5%b9%b4%e7%99%8c%e7%97%87%e7%99%bb%e8%a8%98%e5%b9%b4%e5%a0%b1.pdf 蕭麗珍(2014)•癌症病人社會資本與身心健康關係之研究•未發表的碩士論文•高雄:高雄醫學大學健康科學院醫務管理暨醫療資訊學系。 蔡琇文、賴裕和、陳美伶、陳主智(2000)•癌症疼痛生理感覺特質與疾病不確定感關係之探討•護理研究,8(1),59-69。 蔡麗雲、顧乃平、張澤芸、賴裕和(2001)•癌痛病患的焦慮、憂鬱及其相關因素之探討•新臺北護理期刊,3(1),23-33。 賴虹均(2008)•癌症患者的憂鬱症•腫瘤護理雜誌,8(1),1−11。 蕭思美(2004)•晚期肺癌病患在治療期間的靈性困擾與需求之探討•未發表的碩士論文•臺北:臺灣大學醫學院護理學研究所。 簡淑娟、黃珊、韓彤珍、郭美玲、余芳娥(2005)•乳癌患者之不確定感及其相關因素之探討•腫瘤護理雜誌,5(2),1-13。 蘇剛毅、何肇基、俞松良、施金元、楊泮池(2014)•肺癌關鍵突變基因之意義及檢測•臺灣醫學,18(6),644-653,doi:10.6320/FJM.2014.18(6).04。 羅惠敏、徐南麗、邱慧洳、廖惠娥、劉欣怡(2004)•癌症病患症狀困擾與不確定感關係之探討•慈濟護理雜誌,3(1),72−80。 英文部分 Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., . . . et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376. Arrieta, O., Angulo, L. P., Nunez-Valencia, C., Dorantes-Gallareta, Y., Macedo, E. O., Martinez-Lopez, D., . . . Onate-Ocana, L. F. (2013). Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Annals of Surgical Oncology, 20(6), 1941-1948. doi: 10.1245/s10434-012-2793-5 Axtell, A. (2008). JPM patient information. Depression in palliative care. Journal of Palliative Medicine, 11(3), 529-530. doi: 10.1089/jpm.2008.9943 Bache, X., & Bolton, J. (2005). Depression: diagnosis and management in terminal illness. Hospital Medicine, 66(6), 349-352. doi: 10.12968/hmed.2005.66.6.18415 Bergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994). The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. European Journal of Cancer, 30a(5), 635-642. Carpenter, G., & Cohen, S. (1979). Epidermal growth factor. Annual Review of Biochemistry, 48, 193-216. doi: 10.1146/annurev.bi.48.070179.001205 Chie, W. C., Yang, C. H., Hsu, C., & Yang, P. C. (2004). Quality of life of lung cancer patients: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13. Quality of Life Research, 13(1), 257-262. Chou, T. Y., Chiu, C. H., Li, L. H., Hsiao, C. Y., Tzen, C. Y., Chang, K. T., . . . Tsai, C. M. (2005). Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clinical Cancer Research, 11(10), 3750-3757. doi: 10.1158/1078-0432.ccr-04-1981 Clayton, M. F., Mishel, M. H., & Belyea, M. (2006). Testing a model of symptoms, communication, uncertainty, and well-being, in older breast cancer survivors. Research in Nursing and Health, 29(1), 18-39. doi: 10.1002/nur.20108 Cleeland, C. S. (2007). Symptom burden: multiple symptoms and their impact as patient-reported outcomes. Journal of the National Cancer Institute. Monographs(37), 16-21. doi: 10.1093/jncimonographs/lgm005 Delbaldo, C., Michiels, S., Syz, N., Soria, J. C., Le Chevalier, T., & Pignon, J. P. (2004). Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA, 292(4), 470-484. doi: 10.1001/jama.292.4.470 Detterbeck, F. C., Lewis, S. Z., Diekemper, R., Addrizzo-Harris, D., & Alberts, W. M. (2013). Executive Summary: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), 7S-37S. doi: 10.1378/chest.12-2377 Fortner, B. V., Stepanski, E. J., Wang, S. C., Kasprowicz, S., & Durrence, H. H. (2002). Sleep and quality of life in breast cancer patients. Journal of Pain and Symptom Management, 24(5), 471-480. Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J. Y., . . . Baselga, J. (2003). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. Journal of Clinical Oncology, 21(12), 2237-2246. doi: 10.1200/jco.2003.10.038 Given, B. A., & Given, C. W. (1989). Compliance among patients with cancer. Oncology Nursing Forum, 16(1), 97-103. Hinz, A., Krauss, O., Hauss, J. P., Hockel, M., Kortmann, R. D., Stolzenburg, J. U., & Schwarz, R. (2010). Anxiety and depression in cancer patients compared with the general population. European Journal of Cancer Care (English Language Edition), 19(4), 522-529. doi: 10.1111/j.1365-2354.2009.01088.x Hoffman, A. J., Given, B. A., von Eye, A., Gift, A. G., & Given, C. W. (2007). Relationships among pain, fatigue, insomnia, and gender in persons with lung cancer. Oncology Nursing Forum, 34(4), 785-792. doi: 10.1188/07.onf.785-792 Hsu, T. H., Lu, M. S., Tsou, T. S., & Lin, C. C. (2003). The relationship of pain, uncertainty, and hope in Taiwanese lung cancer patients. Journal of Pain and Symptom Management, 26(3), 835-842. Huang, S. F., Liu, H. P., Li, L. H., Ku, Y. C., Fu, Y. N., Tsai, H. Y., . . . Tsai, S. F. (2004). High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clinical Cancer Research, 10(24), 8195-8203. doi: 10.1158/1078-0432.ccr-04-1245 Jadoon, N. A., Munir, W., Shahzad, M. A., & Choudhry, Z. S. (2010). Assessment of depression and anxiety in adult cancer outpatients: a cross-sectional study. BMC Cancer, 10, 594. doi: 10.1186/1471-2407-10-594 Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, II, . . . Bunn, P. A. (2014). Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA, 311(19), 1998-2006. doi: 10.1001/jama.2014.3741 Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, T. J., Jr., Prager, D., Belani, C. P., . . . Kay, A. C. (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 290(16), 2149-2158. doi: 10.1001/jama.290.16.2149 Lacouture, M. E., Anadkat, M. J., Bensadoun, R. J., Bryce, J., Chan, A., Epstein, J. B., . . . Murphy, B. A. (2011). Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Supportive Care in Cancer, 19(8), 1079-1095. doi: 10.1007/s00520-011-1197-6 LeBlanc, T. W., Nickolich, M., Rushing, C. N., Samsa, G. P., Locke, S. C., & Abernethy, A. P. (2015). What bothers lung cancer patients the most? A prospective, longitudinal electronic patient-reported outcomes study in advanced non-small cell lung cancer. Supportive Care in Cancer. doi: 10.1007/s00520-015-2699-4 Lee, C. K., Brown, C., Gralla, R. J., Hirsh, V., Thongprasert, S., Tsai, C. M., . . . Yang, J. C. (2013). Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. Journal of the National Cancer Institute, 105(9), 595-605. doi: 10.1093/jnci/djt072 Lien, C. Y., Lin, H. R., Kuo, I. T., & Chen, M. L. (2009). Perceived uncertainty, social support and psychological adjustment in older patients with cancer being treated with surgery. Journal of Clinical Nursing, 18(16), 2311-2319. doi: 10.1111/j.1365-2702.2008.02549.x Lin, H. C., Wu, C. H., & Lee, H. C. (2009). Risk factors for suicide following hospital discharge among cancer patients. Psycho-Oncology, 18(10), 1038-1044. doi: 10.1002/pon.1483 Linden, W., Vodermaier, A., Mackenzie, R., & Greig, D. (2012). Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. Journal of Affective Disorders, 141(2-3), 343-351. doi: 10.1016/j.jad.2012.03.025 Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., . . . Haber, D. A. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 350(21), 2129-2139. doi: 10.1056/NEJMoa040938 Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., . . . Nukiwa, T. (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New England Journal of Medicine, 362(25), 2380-2388. doi: 10.1056/NEJMoa0909530 Massie, M. J. (2004). Prevalence of depression in patients with cancer. Journal of the National Cancer Institute. Monographs(32), 57-71. doi: 10.1093/jncimonographs/lgh014 Mishel, M. H., & Braden, C. J. (1988). Finding meaning: antecedents of uncertainty in illness. Nursing Research, 37(2), 98-103, 127. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., . . . Meyerson, M. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304(5676), 1497-1500. doi: 10.1126/science.1099314 Pirl, W. F., Traeger, L., Greer, J. A., Bemis, H., Gallagher, E., Lennes, I., . . . Temel, J. S. (2011). Tumor epidermal growth factor receptor genotype and depression in stage IV non-small cell lung cancer. Oncologist, 16(9), 1299-1306. doi: 10.1634/theoncologist.2011-0116 Pirl, W. F., Traeger, L., Greer, J. A., Jackson, V., Lennes, I. T., Gallagher, E., . . . Temel, J. S. (2013). Depression, survival, and epidermal growth factor receptor genotypes in patients with metastatic non-small cell lung cancer. Palliat Support Care, 11(3), 223-229. doi: 10.1017/S1478951512001071 Reis, N., Beji, N. K., & Coskun, A. (2010). Quality of life and sexual functioning in gynecological cancer patients: results from quantitative and qualitative data. European Journal of Oncology Nursing, 14(2), 137-146. doi: 10.1016/j.ejon.2009.09.004 Savard, J., Simard, S., Ivers, H., & Morin, C. M. (2005). Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: Sleep and psychological effects. Journal of Clinical Oncology, 23(25), 6083-6096. doi: 10.1200/jco.2005.09.548 Sela, R. A. (2007). Screening for depression in palliative cancer patients attending a pain and symptom control clinic. Palliat Support Care, 5(3), 207-217. Sequist, L. V., Yang, J. C., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., . . . Schuler, M. (2013). Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of Clinical Oncology, 31(27), 3327-3334. doi: 10.1200/JCO.2012.44.2806 Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., . . . Seymour, L. (2005). Erlotinib in previously treated non-small-cell lung cancer. New England Journal of Medicine, 353(2), 123-132. doi: 10.1056/NEJMoa050753 Shih, J. Y., Gow, C. H., Yu, C. J., Yang, C. H., Chang, Y. L., Tsai, M. F., . . . Yang, P. C. (2006). Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. International Journal of Cancer, 118(4), 963-969. doi: 10.1002/ijc.21458 Spiro, S. G., Rudd, R. M., Souhami, R. L., Brown, J., Fairlamb, D. J., Gower, N. H., . . . Big Lung Trial, p. (2004). Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax, 59(10), 828-836. doi: 10.1136/thx.2003.020164 Stewart, J. L., Mishel, M. H., Lynn, M. R., & Terhorst, L. (2010). Test of a conceptual model of uncertainty in children and adolescents with cancer. Research in Nursing and Health, 33(3), 179-191. doi: 10.1002/nur.20374 Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., . . . Carroll, K. (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 366(9496), 1527-1537. doi: 10.1016/s0140-6736(05)67625-8 White, K. J., Roydhouse, J. K., & Scott, K. (2011). Psychosocial impact of cutaneous toxicities associated with epidermal growth factor receptor-inhibitor treatment. Clinical Journal of Oncology Nursing, 15(1), 88-96. doi: 10.1188/11.cjon.88-96 Wonghongkul, T., Dechaprom, N., Phumivichuvate, L., & Losawatkul, S. (2006). Uncertainty appraisal coping and quality of life in breast cancer survivors. Cancer Nursing, 29(3), 250-257. Yang, J. C., Wu, Y. L., Chan, V., Kurnianda, J., Nakagawa, K., Saijo, N., . . . Mok, T. S. (2014). Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). Lung Cancer, 83(2), 174-181. doi: 10.1016/j.lungcan.2013.11.021 Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67(6), 361-370. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52936 | - |
dc.description.abstract | 近年來,表皮生長因子受體酪胺酸酶抑制劑 (Epidermal growth factor receptor tyrosine kinase inhibitor, EGFR-TKI) 的發展使得EGFR突變呈陽性(mutation - positive)的晚期肺腺癌病人與EGFR突變呈陰性(wild type)的病人相比,有較長的存活期。然而,不同的EGFR變異型態是否影響病人接受治療後的身體症狀及心理困擾(憂鬱、不確定感),目前國內外皆未有相關的研究。為使臨床醫護人員能於病人初診斷期即識別其在照護需求上的不同,並提早給予介入措施,本研究主要目的為探討晚期肺腺癌病人接受治療後第一個月之憂鬱、不確定感、身體症狀嚴重程度;以及控制症狀嚴重度的影響後,比較不同的EGFR變異型態心理困擾(憂鬱、不確定感)之差異。
本研究採用橫斷式研究法(cross-sectional design),以接受治療後第一個月之新診斷晚期肺腺癌病人為研究對象,以連續取樣方法於台灣北部某醫學中心腫瘤醫學部門診,使用結構式問卷 (基本資料表、歐洲癌症研究與治療組織生活品質量表及肺癌模組量表、醫院焦慮憂鬱中文翻譯量表及Mishel疾病不確定感量表-社區版) 進行身體症狀及心理困擾資料收集,再透過病歷查詢收集癌症分期、EGFR突變型態及治療方式等資料;最後,以描述性統計以及推論性統計 (t檢定、皮爾森積差相關係數及階層多元迴歸) 進行資料分析。 總共收案84人,病人平均年齡為58.8歲,男、女性比例各占47.6%及52.4%,EGFR wild type病人占總病人數57.1%;而EGFR mutation - positive的病人則占42.9%。統計分析結果發現 (1) EGFR wild type的晚期肺腺癌病人之憂鬱程度,顯著的高於EGFR mutation - positive者 (t=3.2, p<.01);(2)不同EGFR變異型態的晚期肺腺癌病人其不確定感程度皆為中度(EGFR wild type: 57.9±10.9; EGFR mutation - positive: 55.2 ±13.3) ,但兩者間未達統計上顯著之差異 (t=1.0, p=.31) ; (3) 整體而言,疲倦及睡眠障礙為晚期肺腺癌病人嚴重度最高的症狀,且EGFR wild type的晚期肺腺癌病人症狀嚴重度較高 (EORTC QLQ-C3O:t=2.72, p=.01;QLQ-LC13:t=2.73, p=.01) ;最後 (4) 控制症狀嚴重度後,不同EGFR變異型態的病人其憂鬱及不確定感程度皆未達統計上顯著差異。 EGFR wild type的晚期肺腺癌病人的身體症狀嚴重度及憂鬱程度都較EGFR mutation-positive者高,但不論病人是何種EGFR變異型態,症狀嚴重度對憂鬱、不確定感等心理困擾帶來的影響是不容忽視的,未來臨床護理人員除了應具備癌症基因型態與其相關治療的知識外,對於因腫瘤及不同治療所帶來之症狀及副作用,許多與腫瘤及治療相關之副作用,更需妥善的介入與處理,以降低治療後之憂鬱、不確定感等心理困擾所帶來的影響,進而提升整體臨床照護品質。 | zh_TW |
dc.description.abstract | Currently, the rapid development of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) leads the promising survival times for lung cancer patients with EGFR mutation. However, limited information has known about patients’ distress in the treatment process. The purposes of this study were to (1) explore the levels of symptom severity and psychological distress (depression and uncertainty), and (2) examine the differences in levels of psychological distress between patients with various types of EGFR mutation after controlling for symptom severity in newly diagnosed advanced lung cancer patients at the first month after receiving anti-cancer treatment.
This is a cross-sectional study with consecutive sampling to recruit newly diagnosed advanced lung cancer patients at the first month after receiving treatment. Patients were recruited and assessed at outpatient department of a medical center in northern Taiwan. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, (EORTC QLQ-C3O), -Lung Cancer 13(EORTC QLQ-LC13), Hospital Anxiety and Depression Scale (HADS), and Mishel's Uncertainty in Illness Scale-Community, (MUIS-C) were applied to assess both physical symptoms and psychological distress. Disease related characteristics were also defined and assessed. Descriptive statistics, correlation analysis and hierarchical multiple regression were used to analyze data. A total of 84 patients were recruited in the study. The mean age of patients was 58.8 years. 47.6% of patients were male; and 52.4% were female. Over half of patients were EGFR wild type (57.1%); and 42.9% were EGFR mutation-positive. The findings showed that (1) the level of depression in patients with EGFR wild type was higher than patients with EGFR mutation-positive (t=3.2, p<.01);(2) level of uncertainty between patients with different EGFR mutation types were all in moderate levels (EGFR wild type: 57.9±10.9; EGFR mutation - positive: 55.2 ±13.3) but not reaching significant (t=1.0, p=.31); (3) in general, fatigue and sleep disturbance were two most severe symptoms in our patients. EGFR wild type patients had higher level of symptom severity in comparison with the EGFR mutation-positive patients (EORTC QLQ-C3O:t=2.72, p=.01;QLQ-LC13:t=2.73, p=.01); (4) after controlling for symptom severity, however, there were no difference in depression and uncertainty between patients with or without EGFR mutation. This study provides the preliminary findings about lung cancer patients’ symptoms severity and psychological distress while having different genomic mutation types. Both groups of patients suffer from psychological distress and patients with wild-types reported severer symptoms. Longitudinal follow-up and providing appropriate interventions to these patients should be conducted for improving patients’ quality of life. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T16:34:53Z (GMT). No. of bitstreams: 1 ntu-104-R02426023-1.pdf: 874626 bytes, checksum: c2b1bbed551e27bf23e565930ab20a2e (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 口試委員會審定書 i
致謝 ii-iii 中文摘要 iv-v 英文摘要 vi-vii 目錄 viii-xi 第一章 緒論 1 第一節 研究動機及重要性 1-2 第二節 研究目的 3 第二章 文獻查證 4 第一節 晚期肺癌的診斷與治療 4-7 第二節 晚期肺癌病人常見的症狀 8-9 第三節 探討晚期肺癌病人的心理困擾及其相關因素...................................10-12 第三章 研究方法 13 第一節 研究架構圖 13 第二節 研究設計 14 第三節 名詞界定與操作性定義 15 第四節 研究工具 16-18 第五節 資料蒐集過程 19 第六節 資料處理與分析 20-21 第七節 研究倫理考量 22 第四章 研究結果 23 第一節 晚期肺癌病人之人口學與疾病治療特質 23-24 第二節 不同EGFR變異型態的晚期肺腺癌病人心理困擾之差異 25-26 第三節 不同EGFR變異型態的晚期肺腺癌病人身體症狀嚴重度之差異 27-28 第四節 控制人口學變項及症狀嚴重度,不同EGFR變異型態心理困擾之差 異............................................................................................................29-33 第五章 討論 ........... 34 第一節 不同疾病特質的晚期肺腺癌病人症狀嚴重度之差異 34-36 第二節 不同疾病特質的晚期肺腺癌病人心理困擾之差異............................37-38 第六章 結論與建議....................................................................................................39 第一節 結論與建議...........................................................................................39-40 第二節 研究限制....................................................................................................41 第七章 參考文獻........................................................................................................42 中文部分............................................................................................................ 42-44 英文部分............................................................................................................ 45-50 圖目錄 圖1 研究架構圖.......................................................................................................13 表目錄 表1. 統計方法一覽表 ............................................................................................. 21 表2. 人口學及疾病治療特質 (N=84)......................................................................24 表3. EGFR變異型態與心理困擾之差異分析 (N=84)..........................................26 表4. EGFR變異型態與身體症狀嚴重度之差異分析 (N=84)..............................28 表5. 肺癌病人憂鬱程度、不確定感程度及身體症狀嚴重度之相關性分析......... (N=84)............................................................................................................... 31 表6. 控制人口學變項及症狀嚴重度,EGFR變異型態與憂鬱程度之差異分析 (N=84)............................................................................................................... 32 表7. 控制人口學變項及症狀嚴重度,EGFR變異型態與不確定感程度之差異 分析 (N=84)......................................................................................................33 | |
dc.language.iso | zh-TW | |
dc.title | 比較不同疾病特質的晚期肺癌病人生心理困擾之差異 | zh_TW |
dc.title | Compare the Differences of Physical and Psychological Distress among Advanced Lung Cancer Patients with Different Disease Type | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 廖唯昱,廖幼婕 | |
dc.subject.keyword | 晚期肺癌,EGFR突變型態,症狀嚴重度,憂鬱,不確定感, | zh_TW |
dc.subject.keyword | Advanced lung carcer,EGFR mutation,Symptom severity,Depression,Uncertainty, | en |
dc.relation.page | 50 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-08-12 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 護理學研究所 | zh_TW |
顯示於系所單位: | 護理學系所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 854.13 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。